You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Rolig A, Rose D, Kivimae S, et al
451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0451